Xcout Intel
Full-Life Technologies competitors & alternatives
The 12 closest competitors and alternatives to Full-Life Technologies among biotechnology companies — ranked by similarity to what Full-Life Technologies actually does, not by market-cap band.
Subscribe to see Full-Life Technologies’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Full-Life Technologies
Full-Life Technologies Limited is a fully integrated global radiopharmaceutical company focused on drug development in oncology, headquartered in Shanghai, China, with additional operations in Europe.
Full-Life Technologies at a glance
Full-Life Technologies is a biotechnology company headquartered in China. It has raised at least $124.3M across the 2 funding rounds on record. Its most recent funding round, Series D, raised $77M in September 2025. Xcout tracks 5 named people at Full-Life Technologies, including Lanny Sun (Chief Executive Officer).
Full-Life Technologies leadership
- Lanny SunChief Executive Officer
- Mark S. de JongChief Technical Officer
- Debora Barton, MDChief Medical Officer
- Fa LiuCo-founder & Chief Scientific Officer
- Philippe van PutGeneral Manager, Europe
Full-Life Technologies funding rounds
At least $124.3M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $77M | 9 named | |
| Series D | $47.3M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Full-Life Technologies competitors
Ranked by semantic similarity — how close each company is to Full-Life Technologies by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Fulgent Pharma LLC is a clinical-stage pharmaceutical company that develops innovative cancer therapeutics using a patented nanoencapsulation technology. The company focuses on improving existing chemotherapy drugs and creating new drug candidates to treat various cancers while reducing toxicity and enhancing drug delivery and safety.
Biotech
Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.
Similar biotechnology company
Flashpoint Therapeutics is a clinical-stage biotechnology research company headquartered in Evanston, Illinois, developing a new class of precision-engineered structural nanomedicines through its proprietary platform.
Similar biotechnology company
PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.
Similar biotechnology company
Pharos iBio Co., Ltd. is a South Korean biotechnology company that uses artificial intelligence and big-data approaches for drug discovery and development. Its pipeline includes oncology candidates such as PHI-101, a FLT3 inhibitor being developed for acute myeloid leukemia and other cancers, serving patients with difficult-to-treat diseases and pharmaceutical development partners.
Biotech
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
Similar biotechnology company
Great Bay Bio is a biotech company headquartered in HKSTP that drives drug development using cutting-edge technologies such as AI and big data mining.
Life Sciences
Crescendo Biologics Ltd., associated with originator organization Crescendo Bioscience LLC, is a biotechnology company headquartered in Cambridge, UK. The firm develops targeted drug pipelines, particularly focusing on oncology and PSMA-positive castration-resistant prostatic cancer treatments.
Biotech
XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensive drug discovery services encompass the entire research and development process, ranging from target validation and hit identification to lead generation, lead optimization, and PCC nomination. These services are adept across diverse therapeutic modalities, such as small molecules, antibodies, peptides, ADCs, and PROTACs. The company's intelligent automation solutions specifically utilize artificial intelligence and automation to facilitate the accelerated discovery and research of novel drugs and materials. Established in 2015 and based in Shenzhen, China, the firm was formerly known as QuantumPharm Inc. before officially changing its name to XtalPi Holdings Limited in December 2024.
Biotech
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. In addition, the company's product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). Further, its product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
Similar biotechnology company
Vibrant Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in China. Founded in July 2019, the firm focuses on revolutionizing protein drug discovery and developing next-generation prodrugs with precise targeting.
Similar biotechnology company
GNI Group Ltd. is a global healthcare company headquartered in Tokyo, Japan, that engages in the entire pharmaceutical value chain ranging from drug discovery to manufacturing.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Full-Life Technologies and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Full-Life Technologiesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →